Business Description
Formed by the successful merger of Griffin-American Healthcare REIT III and Griffin-American Healthcare REIT IV, as well as the acquisition of the business and operations of American Healthcare Investors, American Healthcare REIT is one of the larger healthcare-focused real estate investment trusts globally with assets totaling approximately $4.2 billion in gross investment value. The company benefits from a fully integrated management platform comprised of more than one hundred experienced and skilled professionals, many of whom have worked together since 2006 and have successfully invested in and managed healthcare real estate through multiple market cycles. The management team has a proven track record, deep industry relationships and unparalleled insight into each of the company's assets having built and nurtured the company's international portfolio since its original property acquisition in 2014. The strength of the management team, coupled with the quality of the assets, has American Healthcare REIT poised to capitalize on compelling growth driven by powerful demographic trends. With its 19 million-square-foot, 312-building portfolio of medical office buildings, senior housing communities, skilled nursing facilities and integrated senior health campuses diversified across 36 states and the United Kingdom, the tri-party transaction was a critical step in ideally positioning American Healthcare REIT for a future public listing or IPO on a national stock exchange at the most opportune time. By listing the company's shares on a national exchange, we believe the company will gain greater access to attractive capital that will fuel future growth, broaden our investor base and also provide liquidity to our fellow stockholders. American Healthcare REIT, Inc. operates as a subsidiary of Griffin Capital Company, LLC.
Business History
Generated: Jun 7, 2026 4:30pmPrice Overview
Last updated: Jun 7, 2026 4:47pm (5d ago)Price History (1 Year)
Revenue & Net Income Trend
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
EPS (Diluted): 0.42
Total Equity: $3.32B
Shares: 166,850,000
Total Debt: $1.52B
Cash: $114.84M
EBITDA: $321.98M
Total Debt: $1.52B
Cash: $114.84M
Revenue: $2.26B
Revenue: $2.26B
Revenue: $2.26B
Total Equity: $3.32B
Tax Rate: -45.6%
Equity: $3.32B
Total Debt: $1.52B
Cash: $114.84M
Current Liabilities: $0.00
Long-Term Debt: $1.52B
Total Debt: $1.52B
Total Equity: $3.32B
Shares: 166,850,000
Shares: 166,850,000
CapEx: -$128.56M
Shares: 166,850,000
Stock Price: $47.48
Net Income: $69.81M
Industry Benchmarks
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
Income Statement (Annual)
Last updated: Jun 7, 2026 4:49pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $1.3B | $1.6B | $1.9B | $2.1B | $2.3B |
| Cost of Revenue | $1.1B | $1.3B | $1.5B | $1.7B | $2.2B |
| Gross Profit | $182.0M | $336.0M | $356.8M | $416.8M | $39.7M |
| Operating Expenses | $43.2M | $245.4M | $280.1M | $280.0M | -$128.1M |
| Operating Income | $138.8M | $90.6M | $76.7M | $136.8M | $167.8M |
| Net Income | -$47.8M | -$81.3M | -$71.5M | -$37.8M | $69.8M |
| EBITDA | $159.4M | $233.8M | $324.3M | $315.5M | $322.0M |
| EPS | $-0.72 | $-1.23 | $-1.08 | $-0.29 | $0.42 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 7, 2026 4:30pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $81.6M | $65.1M | $43.4M | $76.7M | $114.8M |
| Total Current Assets | $330.7M | $341.9M | $297.1M | $354.9M | $319.1M |
| Total Assets | $4.6B | $4.8B | $4.6B | $4.5B | $5.4B |
| Current Liabilities | $1.1B | $560.6M | $1.5B | $946.9M | $0 |
| Long-Term Debt | $1.4B | $2.2B | $1.3B | $1.0B | $1.5B |
| Total Liabilities | $2.8B | $3.1B | $3.1B | $2.2B | $2.1B |
| Total Equity | $1.6B | $1.4B | $1.3B | $2.3B | $3.3B |
| Retained Earnings | -$951.3M | -$1.1B | -$1.3B | -$1.5B | -$1.6B |
Cash Flow (Annual)
Last updated: Jun 7, 2026 4:49pm (5d ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | $17.9M | $147.8M | $98.5M | $176.1M | $294.4M |
| Capital Expenditure | -$79.7M | -$71.5M | -$99.8M | -$91.9M | -$128.6M |
| Free Cash Flow | -$61.8M | $76.2M | -$1.3M | $84.1M | $165.9M |
| Acquisitions (net) | $-650,000 | -$18.6M | -$12.9M | $-235,000 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $-382,000 | -$20.7M | $-469,000 | $-14,000 | $238,000 |
| Net Change in Cash | -$26.7M | -$13.6M | -$21.1M | $32.5M | $28.5M |
Analyst Estimates (Annual)
Last updated: Jun 7, 2026 4:27pm (5d ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$2.9B $2.8B – $3.1B
|
$3.0B $3.0B – $3.0B
|
$3.4B $3.4B – $3.7B
|
$3.9B $3.9B – $4.2B
|
| EBITDA |
$470.9M $461.8M – $501.3M
|
$487.0M $483.9M – $490.0M
|
$559.1M $548.3M – $595.1M
|
$638.0M $625.6M – $679.0M
|
| Net Income |
$136.4M $132.2M – $140.5M
|
$176.9M $156.8M – $196.9M
|
$253.6M $247.2M – $274.8M
|
$0 |
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 7, 2026 4:49pm (5d ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | +28.0% | +14.9% | +11.4% | +9.1% |
| Gross Profit Growth | +84.6% | +6.2% | +16.8% | -90.5% |
| Operating Income Growth | -34.7% | -15.3% | +78.3% | +22.7% |
| Net Income Growth | -70.1% | +12.1% | +47.1% | +284.6% |
| EBITDA Growth | +46.6% | +38.7% | -2.7% | +2.1% |
Insider Trading (Recent)
Last updated: Jun 7, 2026 4:49pm (5d ago)All SEC Form 4 codes
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-04-06 | Foster Mark E. | M-Exempt | 2,986.00 | $0.00 | $0 |
| 2026-04-06 | Foster Mark E. | F-InKind | 1,612.00 | $48.09 | $77,521 |
| 2026-04-06 | Foster Mark E. | M-Exempt | 2,986.00 | $0.00 | $0 |
| 2026-04-06 | Oh Stefan K.L. | M-Exempt | 3,185.00 | $0.00 | $0 |
| 2026-04-06 | Oh Stefan K.L. | F-InKind | 1,621.00 | $48.09 | $77,954 |
| 2026-04-06 | Oh Stefan K.L. | M-Exempt | 3,185.00 | $0.00 | $0 |
| 2026-04-06 | Willhite Gabriel M | M-Exempt | 6,768.00 | $0.00 | $0 |
| 2026-04-06 | Willhite Gabriel M | F-InKind | 3,654.00 | $48.09 | $175,721 |
| 2026-04-06 | Willhite Gabriel M | M-Exempt | 6,768.00 | $0.00 | $0 |
| 2026-04-06 | PEAY BRIAN | M-Exempt | 6,768.00 | $0.00 | $0 |
| 2026-04-06 | PEAY BRIAN | F-InKind | 3,654.00 | $48.09 | $175,721 |
| 2026-04-06 | PEAY BRIAN | M-Exempt | 6,768.00 | $0.00 | $0 |
| 2026-04-06 | Prosky Danny | M-Exempt | 15,924.00 | $0.00 | $0 |
| 2026-04-06 | Prosky Danny | F-InKind | 8,596.00 | $48.09 | $413,382 |
| 2026-04-06 | Prosky Danny | M-Exempt | 15,924.00 | $0.00 | $0 |
| 2026-03-26 | Hanson Jeffrey T | A-Award | 42,756.00 | $0.00 | $0 |
| 2026-03-25 | Foster Mark E. | M-Exempt | 7,435.00 | $0.00 | $0 |
| 2026-03-25 | Foster Mark E. | M-Exempt | 3,673.00 | $0.00 | $0 |
| 2026-03-25 | Foster Mark E. | F-InKind | 1,869.00 | $48.25 | $90,179 |
| 2026-03-25 | Foster Mark E. | F-InKind | 3,783.00 | $48.25 | $182,530 |
Dividend History (Last 20)
Last updated: Jun 7, 2026 4:27pm (5d ago)| Date | Dividend | Declaration | Record | Payment |
|---|---|---|---|---|
| 2026-03-31 | $0.25 | 2026-03-18 | 2026-03-31 | 2026-04-17 |
| 2025-12-31 | $0.25 | 2025-12-16 | 2025-12-31 | 2026-01-16 |
| 2025-09-30 | $0.25 | 2025-09-18 | 2025-09-30 | 2025-10-17 |
| 2025-06-30 | $0.25 | 2025-06-20 | 2025-06-30 | 2025-07-18 |
| 2025-03-31 | $0.25 | 2025-03-19 | 2025-03-31 | 2025-04-17 |
| 2024-12-31 | $0.25 | 2024-12-18 | 2024-12-31 | 2025-01-17 |
| 2024-09-20 | $0.25 | 2024-09-06 | 2024-09-20 | 2024-10-18 |
| 2024-06-27 | $0.25 | 2024-06-12 | 2024-06-27 | 2024-07-19 |
| 2024-03-27 | $0.25 | 2024-03-15 | 2024-03-28 | 2024-04-19 |
Narrative Economics
Delvantic AI Findings
Independent read first: AHR is doing what healthcare REITs do post-consolidation — revenue ramping from $1.26B (2021) to $2.26B (2025), a 10.3% CAGR, with the most recent quarter at $650.8M (+20.4% YoY vs Q1 2025's $540.6M). That's not "mature dividend vehicle" growth; that's an operator either acquiring or seeing genuine senior housing RevPOR recovery. Operating CF of $294M and FCF of $166M against a $9.82B market cap is a ~1.7% FCF yield — thin but not catastrophic for a REIT in growth/integration mode. The 2.09% dividend yield is unusually low for a healthcare REIT (peers like Ventas, Welltower run 3-4%), which tells me the market is already pricing in NOI growth, not yield. So this isn't a "yield play disconnected from fundamentals" — it's a senior housing operating recovery story masquerading as a REIT.
Where I disagree with the prior models: the Pre-Flight layer and Rule-Based Classification both pigeonhole this as "dividend-income," but the 2.1% yield and the quarterly revenue acceleration (Q4'24 $542.7M → Q1'26 $650.8M, +20%) say otherwise. This is closer to Welltower's SHOP-recovery trade than to a boring net-lease REIT. The Valuation Synthesis calling it "Disconnected from Fundamentals" on the back of P/E 88x and net margin 3.1% is making the classic REIT-analysis error — net income is depreciation-suppressed; you have to look at FFO/AFFO, which the file doesn't give us but which is almost certainly running at $1.50-1.80/share implying a ~26-30x P/FFO multiple. That's a premium to peers (Welltower ~24x, Ventas ~20x) but not "disconnected" — it's pricing senior housing leverage. The Market Forces "avoid" call and the Synthesis verdict are both anchoring on GAAP metrics inappropriate for the asset class.
The contrarian counter: even granting the SHOP recovery, AHR is externally managed (or was — check the structure), has the smallest scale of the major healthcare REITs, and trades at a premium multiple to better-capitalized peers with longer track records. The balance sheet section is suspiciously blank — no total debt disclosed, which for a REIT is the whole ballgame. If leverage is north of 6x Net Debt/EBITDA (plausible given $9.8B equity cap and likely $3-4B of debt), the equity is a levered bet on cap rate compression. The insider activity is all M-Exempt/F-InKind — option exercises and tax withholding, not conviction buying. Q3'25 NI of $55.9M followed by Q4'25 NI of $10.8M and Q1'26 of $23.7M shows the earnings line is noisy enough that any single-quarter narrative is suspect. And the 9.2% recent YoY revenue growth needs to be decomposed between same-store NOI growth vs. acquisition contribution — the file doesn't tell us, and if it's mostly M&A-driven, the multiple should compress.
Where the data is genuinely thin: no debt figure, no FFO/AFFO, no occupancy or RevPOR breakdown, no breakdown of MOB vs. SHOP vs. SNF mix — for a healthcare REIT these are the only numbers that matter, and we have none of them. The PE/ROE/ROIC anomalies flagged are correct to discount, but more importantly all four are nearly meaningless for a REIT. Citing P/E 88x as evidence of overvaluation, as the synthesis does, is analytically lazy. I dissent from the "Disconnected from Fundamentals" verdict — not because AHR is cheap, but because the synthesis reached the right skepticism through the wrong door. The real bear case is leverage + scale disadvantage + premium multiple to better peers, not GAAP earnings optics.
My verdict: AHR is fully valued to modestly expensive on a SHOP-recovery thesis that's already largely consensus. At $47.48, you're paying a premium P/FFO multiple for a sub-scale operator with undisclosed (likely elevated) leverage and a 2.1% yield that doesn't compensate for the operational risk. Fair value is probably $40-44 absent further senior housing NOI acceleration; the upside case to $55+ requires both continued occupancy
GPT Critique
American Healthcare REIT, Inc. (AHR) presents an intriguing case within the healthcare real estate sector. My analysis of the raw data reveals a company that has demonstrated substantial revenue growth, with a CAGR of 10.3% from 2021 to 2025, culminating in $2.26 billion in revenue. This growth appears to be driven by either acquisitions or a genuine recovery in the revenues per occupied room (RevPOR) within senior housing. AHR's recent quarterly revenue of $650.8M reflects a significant 20.4% increase over the same quarter in the previous year, indicating strong momentum. However, with net margins fluctuating and often razor-thin, the company's profitability is not as robust. The 3.1% net margin in recent quarters coupled with a high price-to-earnings ratio of 88.65 suggests that while the company is growing, it is not translating this growth into proportional earnings due to depreciation impacting net income figures.
Opus argues that AHR should not be classified merely as a "dividend-income" play due to its relatively low 2.09% dividend yield and its revenue growth trajectory, suggesting a shift towards a senior housing operating recovery story. I agree with this assessment. The low dividend yield compared to peers such as Ventas or Welltower indicates that the market anticipates growth rather than purely income. However, where I diverge from Opus is in the valuation and risks associated with AHR. Opus contends that the company's financials, particularly the P/E ratio and net margin, are misleading due to REIT accounting practices that suppress net income. While this is a valid point, the lack of available data on the funds from operations (FFO) or adjusted funds from operations (AFFO) limits the clarity on true cash generation capabilities, making any valuation on P/FFO speculative without these figures.
Moreover, Opus highlights the potential risks related to leverage and scale disadvantages. The absence of total debt figures is concerning and suggests potential vulnerabilities in AHR’s financial structure. Given the typical capital structure of REITs, significant leverage could magnify risks, particularly in a rising interest rate environment. Opus's skepticism about the sustainability of AHR's valuation at $47.48, given its premium multiple and operational risks, aligns with my own concerns about its potential overvaluation.
A careful skeptic would likely argue that both views hinge too heavily on incomplete data, especially around debt levels and cash flow metrics like FFO/AFFO. They might also question the sustainability of the current growth rate given the competitive pressures and structural headwinds in the healthcare real estate market. The lack of granular data on occupancy rates and revenue breakdowns further complicates any confident predictions about future performance.
Advanced Analysis Forensic deep-dive · two lenses
The two lenses point the same way for me: quality at -42 says the assets are fine but capital allocation is actively eroding per-share value (share count up 2.5x in two years, buybacks don't even neutralize SBC), and valuation at -89 says you're paying ~2.3x gross asset value when peers like WELL/VTR/OHI sit at 1.3-1.8x. That's a bad combo — a 'mixed' business priced like a premium compounder. There is no margin of safety here; you're underwriting both a senior-housing NOI inflection AND continued accretive equity-funded M&A, and even if both happen, the dilution drag means per-share upside is muted versus the headline portfolio story.
My play: I'm not initiating at $47.48. I'd set a starter-size limit around $40 (roughly the top of the lens-2 fair range) and only really get interested in the high $30s, where I'd build a 1.5-2% position scaled in over two or three tranches — this is never going to be a core holding given the capital-allocation discipline problem, more of a yield-plus-asset-floor trade. What flips me aggressive: management slowing equity issuance, a buyback that actually exceeds SBC, or a clean SHOP occupancy inflection while the stock is still in the low $40s. What keeps me on the sidelines indefinitely: another big equity raise, or the stock holding $45+ while dilution continues. Today, easy pass.
AHR is a healthcare real estate operator showing genuine top-line and cash-flow progress: revenue climbed from $1.26B (2021) to $2.26B (2025), operating margin recovered from 4.1% in 2023 to 7.4% in 2025, and FCF turned decisively positive at $165.9M. Net income flipped to a $69.8M profit in 2025 after four straight years of losses. For a healthcare REIT, the trajectory of the underlying property cash flow looks like it is finally working, and Altman Z of 3.04 says solvency is not in question.
The quality problem is the capital structure. Diluted shares went from 66.0M (2023) to 130.6M (2024) to 166.9M (2025) — a 2.5x increase in two years, dwarfing the ~21% revenue growth over the same span. Net debt sits at ~$1.4B against just $114.8M of cash, so the balance sheet is a constraint, not a cushion, and equity issuance has clearly been a primary funding tool. Buybacks recover only ~50% of SBC, meaning the company is not even neutralizing employee dilution, let alone returning capital. Beneish M at 3.12 is a statistical flag worth investigating, though the negative accruals (-3.8%) and OCF > NI mechanics actually argue the earnings are cash-backed.
Insider activity is non-directional — the recent tape is entirely option exercises (M) and tax-withholding (F) around RSU vesting, no open-market P or S. Net effect: the operating business is real and improving, but per-share economics are being diluted faster than the business is compounding.
Verify before trusting this (6)
- Whether the 2024-2025 share issuance was for accretive acquisitions (occupancy/NOI per share) or to plug funding gaps
- Reconciliation of the 2025 gross margin collapse to 1.8% vs operating margin expansion — likely an income-statement reclassification
- Tenant/operator concentration in the SHOP and outpatient medical portfolios, especially Trilogy exposure
- Debt maturity ladder and weighted-avg interest rate against the $1.4B net debt
- Whether AFFO/share (the relevant REIT metric) is actually growing despite the share-count surge
- Drivers of Beneish flag — typically DSRI/SGAI from acquisitions; rule out revenue-recognition aggressiveness
AHR trades at ~$9.8B market cap on $4.2B of assets — roughly 2.3x gross asset value, which is rich for a healthcare REIT where peers (WELL, VTR, OHI) generally trade closer to 1.3-1.8x. The e2e synthesis flags 'disconnected from fundamentals,' and I agree with the direction: the price embeds aggressive SHOP/senior-housing recovery and continued accretive deployment, but management has grown the share count ~150% in two years, meaning per-share NAV and FCF growth lag portfolio growth materially. Earnings quality is fine, so no haircut there, but the buyback doesn't even offset SBC.
Deserved value, in my view, sits below the current quote. Healthcare REIT yields in the 3.5-4.5% range on a stabilized basis would imply a price more like $38-$42 given AHR's dividend trajectory and the dilution drag. To justify $47+, you need senior housing NOI to inflect hard AND the equity-funded acquisition machine to keep generating spread — a tall double. Margin of safety here is negative; you're paying for the bull case.
Verify before trusting this (4)
- Same-store NOI growth in SHOP segment — is the senior housing recovery actually accelerating?
- Forward AFFO per share guidance and dilution pace from the next equity raise
- Cap rates on recent acquisitions vs cost of equity capital — is the spread still accretive?
- Dividend coverage on AFFO basis after dilution